Articles Related to Gonzalez M
An Observational Chart Review of a Comparison of Generic to Reference Liposome-Encapsulated Doxorubicin Hydrochloride in Subjects with Epithelial Ovarian Carcinoma Who Have Failed Platinum-Based Chemotherapy
This study tested for the effects of generic liposome-encapsulated doxorubicin hydrochloride (generic doxorubicin) compared to reference-pegylated liposomal doxorubicin hydrochloride (reference doxorubicin) as a treatment for patients afflicted with epithelial ovarian carcinoma whose disease has progressed after platinum-based chemotherapy. Chart-reviews of actual patients enrolled in a community-based NIH trial suggest that both generic and reference liposomal doxorubicin hydrochloride (HCl) are equally effective
as treatment for ovarian cancer carcinoma.
An Observational Study on the Clinical Efficacy of Neramexane in Subjective Tinnitus in a Phase 2 Clinical Trial in a Hispanic Cohort in Laredo, Texas
An observational study was conducted on the efficacy of Neramexane in a small cohort of Hispanic subjects who were diagnosed with moderate to severe subjective tinnitus. Patients were screened using the inclusion and exclusion criteria as outlined by the study sponsor. The study protocol involved daily intake of Neramexane 50 mg/day (for weigh<90 kg) or 75 mg/day (weight>90 kg) for 29 weeks with primary efficacy assessed through audiogram study and 3 electronic self-reporting questionnaires: Tinnitus Handicap Inventory-12 (TBF/THI-12) Scale, Tinnitus Rating Scale (TRS) and Hospital Anxiety and Depression Scale (HADS).
Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas
This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.